Hopes of a blockbuster for Celgene's (CELG) apremalist fade after Phase III results showed just...

|About: Celgene Corporation (CELG)|By:, SA News Editor

Hopes of a blockbuster for Celgene's (CELG) apremalist fade after Phase III results showed just 33% of patients had a 75% reduction in psoriasis vs. 41% in the midstage trial. Management had hoped for $1.1B-$1.75B in peak sales for the drug, a figure few on the Street were buying. (PR)